/
Case 274 T lymphoblastic leukemia with t(5;14)(q35;q32) and lineage switch to acute myeloid Case 274 T lymphoblastic leukemia with t(5;14)(q35;q32) and lineage switch to acute myeloid

Case 274 T lymphoblastic leukemia with t(5;14)(q35;q32) and lineage switch to acute myeloid - PowerPoint Presentation

ellena-manuel
ellena-manuel . @ellena-manuel
Follow
378 views
Uploaded On 2018-03-12

Case 274 T lymphoblastic leukemia with t(5;14)(q35;q32) and lineage switch to acute myeloid - PPT Presentation

Rebecca L King Gerald Wertheim Michele E Paessler The Childrens Hospital of Philadelphia Perelman School of Medicine at the University of Pennsylvania Philadelphia PA Clinical History 13 year old boy ID: 648716

cell del tlx3 ish del cell ish tlx3 q35 q32 myeloid mpo leukemia 2009 der bcl11b p21 100 aml

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Case 274 T lymphoblastic leukemia with t..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Case 274T lymphoblastic leukemia with t(5;14)(q35;q32) and lineage switch to acute myeloid leukemia

Rebecca L. King, Gerald Wertheim, Michele E. PaesslerThe Children’s Hospital of PhiladelphiaPerelman School of Medicine at the University of PennsylvaniaPhiladelphia, PASlide2

Clinical History13 year old boy82% Blasts

300214

4.2Slide3

Bone Marrow : April 2009Slide4

Flow Cytometry: April 2009

CD7+/CD4+

CD14-/CD33-

CD5+/CD2-

cCD3+/TdT+

MPO-Slide5

del(9)(p21)

46,XY,t(5;14)(q35;q32),del(9)(p21.3),del(13)(q14.11q21.1)[7

].

ish

t(5;14)(IGH+;IGH-

), del(9)(p16-)

/46,idem,del(7)(p1?3p?21)[6].

/45,idem,dic(7;8

)(p1?3;p11.2),del(10)(q22)[6

].

ish

dic

(7;8)(7ptel-,7cen+,D7S486+,8cen+,MYC

+)Slide6

DiagnosisT lymphoblastic leukemiat(5;14)(q35;q32)Del 9pSlide7

Clinical HistoryDay 30 of DI: Blasts seen on peripheral smear.

5.99.143

15% blastsSlide8

Bone Marrow: 6 months after Dx

MPOSlide9

Flow Cytometry: October 2009

CD14-/CD33+

cCD3/TdT-

CD15

+

MPO+Slide10

MPO

MPO

CD3

CD3

April

2009

October

2009Slide11

Diagnosis?Therapy-related AMLorLineage switch from T-ALL to AMLSlide12

der(15)t(11;15)

del(7p)

der(4)

del(9)(p21)

1. Cryptic

t(5;14) detected by FISH with IGH

probe

2. Del 9p

67,XY,+Y,der(4)del(4)(q13.1)inv dup(4)(p12pter),del(7)(p11.2p14.1),+8,-9,del(9)(p21.3),-10,-11,-14,-15,der(15) t(11;15)(q13.1;q26),+19,+22[9].ish

der

(15)t(11;15)(MLL+,PML+)

nuc ish 11q23(MLLx3)[89/100]

nuc ish 15q22(PMLx2),17q21.1(RARAx3)[94/100]

nuc ish 9p21(p16x1),9cen(CEP9x2)[90/100]Slide13

FISH: TLX3-BCL11b t(5;14)(q35;q32) present in 84% of nuclei Image courtesy of Rhett Ketterling, MDSlide14

Final DiagnosisT lymphoblastic leukemia with t(5;14)(q35;q32) and lineage switch to acute myeloid leukemia.Slide15

TLX3-BCL11b t(5;14)(q35;q32)25% of pediatric T-ALL5-10% adult T-ALLSingle reported case of myeloid leukemiaSlide16

Coincidence or biological relationship?Slide17

TLX3Homeobox protein related to TLX1Repressive activity on transcription during embryonic developmentDadi et al. Cancer Cell, 2012. TLX1 and TLX3 suppress TCRα rearrangement via ETS1 accounting for the block in T-cell maturation seen in these T-ALLs.

Knockdown of TLX1/3 leads to apoptosis, TCRα rearrangement and cell maturationSlide18

BCL11bSu et al. Blood, 2006. Significance of this gene thought to lie in downstream T-cell-specific cis-activating elements juxtaposed to TLX3 (leads to TLX3 upregulation)Ikawa et al. Science, 2010.

BCL11b is a key checkpoint protein in T-cell development

T/NK/

Myeloid

T cell

Multipotent

HSC

T/B/

NK/

Myeloid

Eryth

/Meg

B-cell

BCL11bSlide19

Therapeutic ImplicationsMixed lineage acute leukemias are difficult to treat and have poor overall survivalAim therapy at myeloid or T component?Potential for targeted therapy aimed at suppressing TLX3 to overcome the differentiation “block”Slide20

Patient Follow-UpSwitched from T-ALL to AML therapyDid not achieve second remissionDied 2 months following AML diagnosisSlide21

AcknowledgementsCHOPGerald WertheimMichele PaesslerJackie BiegelPennDale Frank

Mayo ClinicRhett Ketterling